KalVista Pharmaceuticals

November 29, 2019

Upcoming events – Kalvista aims for acuity and a me-too from Sanofi approaches

As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.

August 20, 2019

Where now for Oxurion?

The failure of its lead product in diabetic macular oedema, a limited pipeline and limited cash leaves Oxurion with few options.

May 24, 2019

Upcoming events – key tests approach for Biogen and Kalvista

Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.

October 11, 2017

Kalvista leads the kallikrein eye disease pipeline

August 31, 2011

Therapeutic Focus - Looking beyond VEGF in diabetic eye disease